NovaBay Pharmaceuticals Receives 2nd Major NeutroPhase Order for 150,000 Units from China Pioneer Pharma

By October 27, 2014

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that its partner China Pioneer Pharma Holdings, Limited (HK Stock Code: 01345), a leading marketer of branded pharmaceutical products and medical devices in China, has ordered an additional 150,000 units of NovaBay’s NeutroPhase® Skin and Wound Cleanser. The order will enable Pioneer to launch the product in early 2015 throughout mainland China.

“China will be a significant market for NeutroPhase, because the product can bring a major improvement in medical care to China and in the quality of patients’ lives.” said Dr. Ron Najafi, Chairman and CEO of NovaBay

The order follows the clearance in August of NeutroPhase for sale in China by China’s Food and Drug Administration.

“We’re anticipating a large demand for NeutroPhase in China, because the product will help Chinese doctors address major unmet medical needs,” explained Paul Li, Chairman, Executive Director and Chief Executive Officer of Pioneer Pharma.

China is now experiencing what experts call a ‘catastrophic’ epidemic of diabetes. According to estimates provided by the International Diabetes Federation and the American Medical Association, 100 million Chinese already suffer from this condition and from the side effects of diabetes, such as diabetic ulcers and other chronic wounds.

NovaBay’s FDA-cleared NeutroPhase has shown remarkable properties in the management of these wounds. As cited in a paper published in the peer-reviewed International Journal of Burns and Trauma, “Patients showed a profound improvement after treatment with NeutroPhase® wound cleanser with and without NPWT (negative pressure wound therapy).  Lab testing has shown NeutroPhase® was non-toxic to living and clinically we see no negative effects.”

NeutroPhase has also been used successfully as part of a new treatment regimen to save the lives and limbs of victims of life-threatening flesh-eating disease, as Dr. John Crew, director of the Advanced Wound Care Center at Seton Medical Center in Daly City, Calif and NovaBay researchers reported in the journal WOUNDS.

China has the highest number of reported cases of necrotizing fasciitis, or ‘flesh-eating’ disease of any nation in the world.

NeutroPhase contains a substance produced naturally by the immune system as a first defense against microbial invaders. Laboratory tests show that NeutroPhase not only kills bacteria that infect wounds and cause necrotizing fasciitis, it also neutralizes toxins produced by both bacteria and the immune system that impede healing and destroy healthy tissue. Those properties seen in laboratory testing enable NeutroPhase to be used effectively as the wound cleansing agent to address acute infections and aid in the management of wound care.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: Aganocide® compounds, led by auriclosene, and its FDA cleared Neutrox™ Family of Products: NeutroPhase® for wound care, Advanced i-Lid™ Cleanser for the eye care market, and CelleRx™ for the dermatology market. Neutrox is a pure form of hypochlorous acid (HOCl) produced by NovaBay’s proprietary andpatented manufacturing process.

About China Pioneer Pharma Holdings, Limited
China Pioneer Pharma is one of the largest comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China, Founded in 1996, which has an 18-year operating history. Currently, China Pioneer Pharma has a product portfolio of over 30 pharmaceutical products covering a wide range of therapeutic areas, and medical devices covering four medical specialties. And it has over 240 in-house marketing and promotion employees, over 1,000 third-party promotion partners and over 500 distributors. China Pioneer Pharma sold its products through its nationwide marketing, promotion and channel management service network to a total of over 26,000 hospitals and other medical institutions and over 95,000 pharmacies across 31 provinces, municipalities and autonomous regions in China. For more information, please visit www.pioneer-pharma.com.

Forward-looking Statements
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding regulatory approvals for our products, the anticipated market acceptance of our products, and the company’s expected future financial results. The words “will” “estimated” “anticipate” and “expect” are intended to identify these forward-looking statements.  Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in product development, clinical trials, regulatory approval, production and marketing of the company’s products, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to the company and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

For investor information, please contact:
Thomas J. Paulson  
Chief Financial Officer
510-899-8809
Contact Thomas Paulson

TOP